TherapeuticsMD, Inc. (TXMD)
USD 1.14
(5.56%)
USD 1.14
(5.56%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.3 Million USD | -98.14% |
| 2022 | 69.96 Million USD | -19.54% |
| 2021 | 86.95 Million USD | 34.03% |
| 2020 | 64.87 Million USD | 30.67% |
| 2019 | 49.64 Million USD | 208.38% |
| 2018 | 16.09 Million USD | -4.04% |
| 2017 | 16.77 Million USD | -13.32% |
| 2016 | 19.35 Million USD | -3.9% |
| 2015 | 20.14 Million USD | 34.05% |
| 2014 | 15.02 Million USD | 71.23% |
| 2013 | 8.77 Million USD | 129.85% |
| 2012 | 3.81 Million USD | 82.84% |
| 2011 | 2.08 Million USD | 4230.79% |
| 2010 | 48.21 Thousand USD | 356.21% |
| 2009 | 10.56 Thousand USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | -100.0% |
| 2006 | 1 Million USD | 7.57% |
| 2005 | 934.52 Thousand USD | 50.26% |
| 2004 | 621.92 Thousand USD | 42.13% |
| 2003 | 437.58 Thousand USD | 52.68% |
| 2002 | 286.6 Thousand USD | -13.82% |
| 2001 | 332.57 Thousand USD | -9.63% |
| 2000 | 368.02 Thousand USD | 71.82% |
| 1999 | 214.19 Thousand USD | 10.42% |
| 1998 | 193.97 Thousand USD | 0.45% |
| 1997 | 193.09 Thousand USD | -20.88% |
| 1996 | 244.05 Thousand USD | 24.62% |
| 1995 | 195.83 Thousand USD | -0.48% |
| 1994 | 196.78 Thousand USD | -2.19% |
| 1993 | 201.18 Thousand USD | 0.0% |
| 1992 | - USD | 0.0% |
| 1991 | - USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 313 Thousand USD | -37.65% |
| 2024 Q2 | 234 Thousand USD | -25.24% |
| 2023 Q2 | 437 Thousand USD | 5.05% |
| 2023 Q3 | -53 Thousand USD | -112.13% |
| 2023 Q4 | 502 Thousand USD | 1047.17% |
| 2023 Q1 | 416 Thousand USD | -63.89% |
| 2023 FY | 1.3 Million USD | -98.14% |
| 2022 FY | 69.96 Million USD | -19.54% |
| 2022 Q4 | 1.15 Million USD | -94.49% |
| 2022 Q3 | 20.91 Million USD | -26.76% |
| 2022 Q1 | 19.33 Million USD | 3.51% |
| 2022 Q2 | 28.56 Million USD | 47.73% |
| 2021 Q3 | 25.4 Million USD | 10.46% |
| 2021 Q2 | 23 Million USD | 15.78% |
| 2021 Q1 | 19.86 Million USD | -12.01% |
| 2021 Q4 | 18.67 Million USD | -26.48% |
| 2021 FY | 86.95 Million USD | 34.03% |
| 2020 FY | 64.87 Million USD | 30.67% |
| 2020 Q1 | 12.25 Million USD | -22.96% |
| 2020 Q2 | 10.7 Million USD | -12.65% |
| 2020 Q3 | 19.34 Million USD | 80.76% |
| 2020 Q4 | 22.57 Million USD | 16.72% |
| 2019 Q1 | 3.94 Million USD | -22.46% |
| 2019 Q3 | 23.71 Million USD | 290.2% |
| 2019 FY | 49.64 Million USD | 208.38% |
| 2019 Q2 | 6.07 Million USD | 54.03% |
| 2019 Q4 | 15.9 Million USD | -32.96% |
| 2018 Q4 | 5.08 Million USD | 46.52% |
| 2018 Q2 | 3.76 Million USD | -0.28% |
| 2018 Q1 | 3.77 Million USD | -8.51% |
| 2018 Q3 | 3.47 Million USD | -7.69% |
| 2018 FY | 16.09 Million USD | -4.04% |
| 2017 Q2 | 4.25 Million USD | 6.65% |
| 2017 FY | 16.77 Million USD | -13.32% |
| 2017 Q4 | 4.12 Million USD | -6.64% |
| 2017 Q3 | 4.41 Million USD | 3.93% |
| 2017 Q1 | 3.98 Million USD | -11.19% |
| 2016 Q1 | 4.93 Million USD | -12.43% |
| 2016 Q2 | 4.4 Million USD | -10.69% |
| 2016 Q3 | 5.53 Million USD | 25.72% |
| 2016 Q4 | 4.48 Million USD | -18.94% |
| 2016 FY | 19.35 Million USD | -3.9% |
| 2015 Q2 | 4.84 Million USD | 8.33% |
| 2015 FY | 20.14 Million USD | 34.05% |
| 2015 Q4 | 5.62 Million USD | 8.47% |
| 2015 Q3 | 5.19 Million USD | 7.06% |
| 2015 Q1 | 4.47 Million USD | 5.11% |
| 2014 FY | 15.02 Million USD | 71.23% |
| 2014 Q2 | 3.75 Million USD | 32.55% |
| 2014 Q3 | 4.18 Million USD | 11.58% |
| 2014 Q1 | 2.83 Million USD | -1.13% |
| 2014 Q4 | 4.25 Million USD | 1.71% |
| 2013 FY | 8.77 Million USD | 129.85% |
| 2013 Q4 | 2.86 Million USD | 24.76% |
| 2013 Q3 | 2.29 Million USD | 10.28% |
| 2013 Q2 | 2.08 Million USD | 35.37% |
| 2013 Q1 | 1.53 Million USD | 23.9% |
| 2012 Q3 | 1.03 Million USD | 26.53% |
| 2012 Q4 | 1.24 Million USD | 19.71% |
| 2012 Q2 | 819.15 Thousand USD | 13.5% |
| 2012 Q1 | 721.69 Thousand USD | -65.4% |
| 2012 FY | 3.81 Million USD | 82.84% |
| 2011 Q3 | 2100.00 USD | 0.0% |
| 2011 FY | 2.08 Million USD | 4230.79% |
| 2011 Q1 | - USD | -100.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q4 | 2.08 Million USD | 99237.0% |
| 2010 Q2 | 5734.00 USD | -62.59% |
| 2010 Q4 | 20.36 Thousand USD | -7.94% |
| 2010 Q3 | 22.12 Thousand USD | 285.77% |
| 2010 Q1 | 15.32 Thousand USD | 45.04% |
| 2010 FY | 48.21 Thousand USD | 356.21% |
| 2009 Q2 | - USD | 0.0% |
| 2009 FY | 10.56 Thousand USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q4 | 10.56 Thousand USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2007 Q3 | 242.86 Thousand USD | 7.54% |
| 2007 FY | - USD | -100.0% |
| 2007 Q4 | - USD | -100.0% |
| 2007 Q2 | 225.83 Thousand USD | 1.97% |
| 2007 Q1 | 221.47 Thousand USD | 17.86% |
| 2006 Q1 | 232.73 Thousand USD | -17.35% |
| 2006 Q3 | 368.38 Thousand USD | 76.23% |
| 2006 FY | 1 Million USD | 7.57% |
| 2006 Q4 | 187.9 Thousand USD | -48.99% |
| 2006 Q2 | 209.03 Thousand USD | -10.18% |
| 2005 Q1 | 194.42 Thousand USD | 11.05% |
| 2005 Q2 | 204.16 Thousand USD | 5.01% |
| 2005 FY | 934.52 Thousand USD | 50.26% |
| 2005 Q3 | 254.34 Thousand USD | 24.58% |
| 2005 Q4 | 281.58 Thousand USD | 10.71% |
| 2004 Q4 | 175.07 Thousand USD | -0.92% |
| 2004 Q1 | 131.07 Thousand USD | 7.18% |
| 2004 Q2 | 139.06 Thousand USD | 6.1% |
| 2004 Q3 | 176.7 Thousand USD | 27.07% |
| 2004 FY | 621.92 Thousand USD | 42.13% |
| 2003 Q2 | 121.56 Thousand USD | 17.9% |
| 2003 FY | 437.58 Thousand USD | 52.68% |
| 2003 Q4 | 122.29 Thousand USD | 34.97% |
| 2003 Q3 | 90.61 Thousand USD | -25.46% |
| 2003 Q1 | 103.1 Thousand USD | 6.21% |
| 2002 Q4 | 97.08 Thousand USD | 30.03% |
| 2002 Q1 | 49.32 Thousand USD | 7.23% |
| 2002 Q2 | 65.53 Thousand USD | 32.88% |
| 2002 FY | 286.6 Thousand USD | -13.82% |
| 2002 Q3 | 74.66 Thousand USD | 13.92% |
| 2001 Q2 | 93.14 Thousand USD | -23.88% |
| 2001 Q1 | 122.36 Thousand USD | -6.28% |
| 2001 FY | 332.57 Thousand USD | -9.63% |
| 2001 Q4 | 45.99 Thousand USD | -35.28% |
| 2001 Q3 | 71.07 Thousand USD | -23.69% |
| 2000 Q3 | 91.58 Thousand USD | 18.02% |
| 2000 Q2 | 77.6 Thousand USD | 11.0% |
| 2000 Q1 | 69.91 Thousand USD | 1.85% |
| 2000 FY | 368.02 Thousand USD | 71.82% |
| 2000 Q4 | 130.56 Thousand USD | 42.56% |
| 1999 Q1 | 40.24 Thousand USD | 0.0% |
| 1999 Q3 | 58.11 Thousand USD | 23.83% |
| 1999 Q2 | 46.92 Thousand USD | 16.61% |
| 1999 FY | 214.19 Thousand USD | 10.42% |
| 1999 Q4 | 68.64 Thousand USD | 18.11% |
| 1998 FY | 193.97 Thousand USD | 0.45% |
| 1997 FY | 193.09 Thousand USD | -20.88% |
| 1996 FY | 244.05 Thousand USD | 24.62% |
| 1995 FY | 195.83 Thousand USD | -0.48% |
| 1994 FY | 196.78 Thousand USD | -2.19% |
| 1993 FY | 201.18 Thousand USD | 0.0% |
| 1992 FY | - USD | 0.0% |
| 1991 FY | - USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Intra-Cellular Therapies, Inc. | 464.37 Million USD | 99.72% |
| PainReform Ltd. | - USD | -Infinity% |
| Alvotech | 91.43 Million USD | 98.576% |
| Collegium Pharmaceutical, Inc. | 566.76 Million USD | 99.77% |
| ANI Pharmaceuticals, Inc. | 486.81 Million USD | 99.733% |
| Aquestive Therapeutics, Inc. | 50.58 Million USD | 97.426% |
| Journey Medical Corporation | 79.18 Million USD | 98.356% |
| Dynavax Technologies Corporation | 232.28 Million USD | 99.439% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | 98.881% |
| Bright Green Corporation | 401.49 Thousand USD | -224.291% |
| Pacira BioSciences, Inc. | 674.97 Million USD | 99.807% |
| Embecta Corp. | 1.12 Billion USD | 99.884% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | 94.596% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | 94.596% |
| SCYNEXIS, Inc. | 140.14 Million USD | 99.071% |
| Petros Pharmaceuticals, Inc. | 5.82 Million USD | 77.638% |
| Silver Spike Investment Corp. | 11.72 Million USD | 88.893% |
| China SXT Pharmaceuticals, Inc. | 1.92 Million USD | 32.486% |
| Alpha Teknova, Inc. | 36.68 Million USD | 96.451% |
| Safety Shot Inc | 202.67 Thousand USD | -542.424% |
| Procaps Group, S.A. | 409.92 Million USD | 99.682% |
| Cosmos Health Inc. | 53.37 Million USD | 97.561% |
| Theratechnologies Inc. | 81.76 Million USD | 98.408% |
| Harrow Health, Inc. | 130.19 Million USD | 99.0% |
| Sonoma Pharmaceuticals, Inc. | 12.73 Million USD | 89.776% |
| Biofrontera Inc. | 34.07 Million USD | 96.179% |
| DURECT Corporation | 8.54 Million USD | 84.768% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 99.786% |
| Cronos Group Inc. | 88.84 Million USD | 98.534% |
| OptiNose, Inc. | 70.98 Million USD | 98.166% |
| Ironwood Pharmaceuticals, Inc. | 442.73 Million USD | 99.706% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| RedHill Biopharma Ltd. | 6.51 Million USD | 80.01% |
| Organogenesis Holdings Inc. | 433.14 Million USD | 99.699% |
| Guardion Health Sciences, Inc. | 12.24 Million USD | 89.37% |
| Cumberland Pharmaceuticals Inc. | 39.55 Million USD | 96.708% |
| Radius Health, Inc. | 2.88 Billion USD | 99.955% |
| Universe Pharmaceuticals INC | 32.3 Million USD | 95.97% |
| ProPhase Labs, Inc. | 44.38 Million USD | 97.067% |
| Phibro Animal Health Corporation | 1.01 Billion USD | 99.872% |
| Procaps Group S.A. | 409.92 Million USD | 99.682% |
| Viatris Inc. | 15.42 Billion USD | 99.992% |
| Rockwell Medical, Inc. | 83.61 Million USD | 98.443% |
| Aytu BioPharma, Inc. | 81 Million USD | 98.393% |
| SIGA Technologies, Inc. | 139.91 Million USD | 99.069% |
| Tilray Brands, Inc. | 788.94 Million USD | 99.835% |
| Lifecore Biomedical, Inc. | 128.26 Million USD | 98.985% |
| Shineco, Inc. | 9.8 Million USD | 86.717% |
| PetIQ, Inc. | 1.1 Billion USD | 99.882% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Incannex Healthcare Limited | 12 Thousand USD | -10750.0% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 99.931% |
| Alimera Sciences, Inc. | 80.75 Million USD | 98.388% |
| Assertio Holdings, Inc. | 152.06 Million USD | 99.144% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Clever Leaves Holdings Inc. | 17.41 Million USD | 92.525% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -20.958% |
| Avadel Pharmaceuticals plc | 27.96 Million USD | 95.344% |
| Hempacco Co., Inc. | 4.04 Million USD | 67.817% |
| Talphera, Inc. | 651 Thousand USD | -100.0% |
| Alvotech | 91.43 Million USD | 98.576% |
| Eagle Pharmaceuticals, Inc. | 316.61 Million USD | 99.589% |
| Lantheus Holdings, Inc. | 1.29 Billion USD | 99.9% |
| Currenc Group, Inc. | 53.25 Million USD | 97.555% |
| Kamada Ltd. | 144.75 Million USD | 99.101% |
| Indivior PLC | 1.09 Billion USD | 99.881% |
| Evoke Pharma, Inc. | 5.18 Million USD | 74.868% |
| Flora Growth Corp. | 76.07 Million USD | 98.288% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -20.958% |
| Evolus, Inc. | 202.08 Million USD | 99.356% |
| HUTCHMED (China) Limited | 837.99 Million USD | 99.845% |
| Amphastar Pharmaceuticals, Inc. | 644.39 Million USD | 99.798% |
| Akanda Corp. | 2.16 Million USD | 39.724% |